11 Newly-Listed NASDAQ Stocks to Buy Now
IPO activity is starting to recover after a quiet stretch.
Caris Life Sciences Inc. (CAI)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Coatue Management Philippe Laffont | 9,819,992 | $264,943,384 | -4% | 0.66% |
| 2. | Braidwell LP Alex Karnal | 7,816,142 | $210,879,512 | +7% | 6.74% |
| 3. | Point State Capital Zach Schreiber | 6,718,707 | $181,270,715 | +73% | 2.67% |
| 4. | Millennium Management Israel Englander | 3,652,647 | $98,548,416 | -8% | 0.04% |
| 5. | OrbiMed Advisors Samuel Isaly | 3,116,011 | $84,069,977 | +3% | 1.72% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.09 | 4,184 | $100,792.56 | 9,184 | 2025-11-07 | Filing | |
| $23.85 | 400 | $9,540.00 | 460,777 | 2025-11-07 | Filing | |
| $21.00 | 7,500 | $157,500.00 | 123,591 | 2025-06-20 | Filing | |
| $21.00 | 30,000 | $630,000.00 | 162,428 | 2025-06-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.16 | 1,400 | $38,017.56 | 99,571 | 2025-12-11 | Filing | |
| $26.56 | 60,850 | $1,616,443.74 | 100,971 | 2025-12-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,256,615 | $546,523,473 | 100% | |
| 2. | 19,385,399 | $523,018,065 | 53.72% | |
| 3. | 14,217,768 | $383,595,380 | 0.02% | |
| 4. | 3,800,922 | $102,548,876 | 0.08% | |
| 5. | 2,445,281 | $65,973,700 | 0% |
News See All
Cannaccord Genuity Asserts Hold Stance on Caris Life Sciences, Inc. (CAI) On Oncology Pipeline Development
Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best biotech stocks to buy according to Wall Street analysts.
15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
Caris Life Sciences, Inc. (NASDAQ:CAI) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to the Caris Life Sciences Third Quarter 2025 Earnings Call. My name is Shannon, and I will be your coordinator today. [Operator Instructions].
Caris Life Sciences, Inc. (CAI) Soars 81% YoY with $181M Q2 Revenue
Caris Life Sciences, Inc.
12 Healthcare Stocks with Insider Buying in 2025
In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, with divergent trends in technology adoption, investment, and fundraising.
Strong Performance Lifted Caris Life Sciences (CAI) in Q2
ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S.
Caris Life Sciences, Inc. (CAI) Secures FDA Nod for Revolutionary Tumor Profiling Test
A pivotal development came with the FDA approval of Caris’s MI Cancer Seek platform, the first diagnostic to combine whole exome and whole transcriptome sequencing on a single test for both adult and...
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
Mario Gabelli is Doubling Down on These 5 Stocks
In this article, we discuss the 5 stocks that Mario Gabelli is doubling down on.
Hedge Fund Resource Center